

ALEXION: Soliris' Label Expansion & Diversification to Perk ALXN Up!

https://marketpublishers.com/r/A95C6D2AB65EN.html

Date: April 2012

Pages: 5

Price: US\$ 140.00 (Single User License)

ID: A95C6D2AB65EN

Abstracts

An another impressive quarter – robust sales in Paroxysmal Nocturnal Hemoglobinuria (PNH), steady uptake in atypical Hemolytic Uremic Syndrome (aHUS) indication, and label expansion in other rare and high unmet need indications of Soliris; we expect the growth trajectory continues in the long term. Positive PhII clinical data of Asfotase alfa (ENB-0040, PhII/III, hypophosphatasia, HPP) justifies the acquisition of Enobia and thus, ALXN's diversification strategy. ALXN's experience in developing and marketing orphan drugs should intact its value, despite any disappointments... For more details, please read our report released on April 25, 2012 on ALXN, titled "Soliris' Label Expansion & Diversification to Perk ALXN Up!"



Contents

COMPANIES MENTIONED

ALEXION



I would like to order

Product name: ALEXION: Soliris' Label Expansion & Diversification to Perk ALXN Up!

Product link: https://marketpublishers.com/r/A95C6D2AB65EN.html

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A95C6D2AB65EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms